Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone

Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone

At present, prostate-specific antigen (PSA) is used as a clinical biomarker for prostate cancer (PCa) diagnosis; however, a large number of patients with benign prostate hyperplasia (BPH) with PSA levels in the ʻgray areaʼ (4–10 ng/ml) are currently subjected to unnecessary biopsy due to overdiagnos...

Full description

Bibliographic Details
Main Authors: SALIDO-GUADARRAMA, ALBERTO IVAN, MORALES-MONTOR, JORGE GUSTAVO, RANGEL-ESCAREÑO, CLAUDIA, LANGLEY, ELIZABETH, PERALTA-ZARAGOZA, OSCAR, COLIN, JOSE LUIS CRUZ, RODRIGUEZ-DORANTES, MAURICIO
Format: Online
Language:English
Published: D.A. Spandidos 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878542/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878542/

Similar Items